FB pixel image
Research & Discoveries


Menu Eggshell Membrane (NEM)

NEM® Brand Eggshell Membrane Effective in the Treatment of Pain Associated with Knee and Hip Osteoarthritis

Results From A Six Center, Open Label German Clinical Study


Introduction NEM® brand eggshell mspan style="font-style:italic;"brane is a novel dietary supplspan style="font-style:italic;"ent that contains naturally occurring glycosaminoglycans and proteins essential for maintaining healthy joint and connective tissues. A six-center, open label clinical study was conducted to evaluate the efficacy and safety of NEM® as a treatment for pain and inflexibility associated with osteoarthritis of the knee and/or hip in a European population.

Methods Forty-four subjects received oral NEM® 500 mg once daily for eight weeks. The primary outcome measure was to evaluate the mean effectiveness of NEM® in relieving general pain associated with moderate osteoarthritis of the knee and/or hip utilizing a 10-question, abbreviated questionnaire based on the WOMAC osteoarthritis questionnaire. The primary treatment response endpoints were at 10, 30, and 60 days. The clinical assessment was performed on the per protocol population.

Results Supplspan style="font-style:italic;"entation with NEM® produced a significant treatment response from baseline at 10 days (Q1-6 & Q9)(8.6% to 18.1% improvspan style="font-style:italic;"ent) and at 30 & 60 days for all nine pain-related questions evaluated (22.4% to 35.6% improvspan style="font-style:italic;"ent). Additionally, there was a significant treatment response from baseline at 30 & 60 days for stiffness (Q10)(27.4% to 29.3% improvspan style="font-style:italic;"ent). In a Patient’s Global Assessment, greater than 59% of patients rated the efficacy of NEM® as good or very good following 60 days of supplspan style="font-style:italic;"entation. Physicians also rated the treatment effective in subjects, with greater than 75% having moderate or significant improvspan style="font-style:italic;"ent from baseline after 60 days. There were no serious adverse events reported during the study and the treatment was reported to be well tolerated by study participants.

Conclusions NEM® is an effective and safe therapeutic option for the treatment of pain associated with osteoarthritis of the knee and/or hip. Supplspan style="font-style:italic;"entation with NEM®, 500 mg taken once daily, significantly reduced pain, both rapidly (10 days) and continuously (60 days). It also showed clinically meaningful results from a brief responder analysis, dspan style="font-style:italic;"onstrating that significant proportions of treated patients will be helped considerably from NEM® supplspan style="font-style:italic;"entation. This study dspan style="font-style:italic;"onstrates that results from previous clinical studies can likely be extended to the broader European population."

Read Article